TLP
FATE icon

Tri Locum Partners’s Fate Therapeutics FATE Stock Holding History

Tri Locum Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-190,345
Closed -$7.38M – 55
2022
Q1 		$7.38M Buy
190,345
+48,313
+34% +$1.87M 2.88% 19
2021
Q4 		$8.31M Buy
+142,032
New +$8.05M 3.27% 14

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Tri Locum Partners's FATE Position: Q2 2022 in Review

Tri Locum Partners sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 190,345 shares — an estimated $7.38M sold.

Tri Locum Partners first reported a position in FATE in Q4 2021 and held it in 2 quarters. The position peaked at $8.31M in Q4 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Tri Locum Partners reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Tri Locum Partners sold 190,345 Fate Therapeutics shares in Q2 2022, an estimated $7.38M.
  • Tri Locum Partners first reported a position in Fate Therapeutics in Q4 2021 and held it in 2 quarters.
  • Tri Locum Partners's Fate Therapeutics position peaked at $8.31M in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Tri Locum Partners's 13F filing for Q2 2022, filed 15 Aug 2022.